Floatz logo

Ioc

Immune System Diseases

National Cancer Institute (NCI)Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Immune System Diseases cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Indapta Therapeutics, INC.
Phase 2BB
Fludarabine
Indapta Therapeutics, INC.
Phase 2BB
LIDOCAINE
Ciusss de L'Est de l'Île de Montréal
Phase 4BB
Strimvelis
Fondazione Telethon
Phase 4B
Ibrutinib
Oncternal Therapeutics, Inc
Phase 3B

View all 38 →

Same molecule, other indications

Ioc is also rated in:

mature T-cell and NK-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
lymphoproliferative syndromeDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →